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of variation were 6% and 7O/i respectively and the sensitivity of the assay was 3.9 ng/ml lipocortin 1. T h e method appeared to be specific as none of the other peptides tested, which were known to be present in the tissue extracts (vasopressin, corticotropin releasing factor-4 1, corticotropin and somatostatin), cross-reacted with the antibody (data not shown).
Lipocortin 1 was readily detectable in all areas studied. However, its concentration was significantly higher (I>< 0.0 1, [ 17, 181. T h e significance of these observations remains to be elucidated. However the assay described here will be a useful tool for studies on the physiological and pharmacological roles of lipocortin 1.
We are grateful to Dr J. L. Browning. Biogen Research Corporation. U.S.A., for the lipocortin antiserum and recombinant human lipocortin I and to the M.R.C. for financial support.
In the placenta, eicosanoid biosynthesis is carefully controlled. This is important as some of these compounds are thought to be involved in promoting uteroplacental blood flow. A s the production of vasoactive eicosanoids changes dramatically during certain pathological conditions in human pregnancy it was proposed that it is the loss of control mechanisms which causes diseases like preeclampsia 11 I.
However, the nature of the mechanisms which regulate eicosanoid production in placenta is not known. Two enzymes which are thought to be sites of regulation are phospholipase A2 (PLA,) and phospholipase C plus diacylglycerol lipase. It is likely that direct and indirect controls act on these enzymes. Primary messengers (hormones, cytokines, Abbreviations used: PLA2. phospholipase A,; AA, arachidonic acid. growth factors, etc.) are held to exert direct control by either activation of G protein-dependent pathways 121 or receptor tyrosine kinase-dependent signal transduction pathways 13 I.
However, for neither pathway phospholipase activation has directly been shown. O n the other hand, Tyr-phosphorylation of some members of a newly recognized family of calcium-sensitive and membrane-associated proteins has been reported. These proteins are now known to belong to the lipocortin/calpactin family [4] . Some of these proteins have been also reported as potent inhibitors of PLAz and their modification induced by phosphorylation is proposed to modulate their activity 151.
We have partially purified two species of PLA, from human placenta which we refer to as PLA2-M and PLA2-S [6] . PLAz activity was measured as the release of palmitic acid from phospholipid liposome substrate. Liposomes were generated by ultrasonication of 1,2-dipalmitoyl phosphatidylcholine. A portion of it carried radioactively labelled palmitic acid esterified in its sn2 position. PLA2-M was obtained by extracting placental membranes with EGTA and was further purified by sequential chromatography on gel
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BIOCHEMICAL SOCIETY TRANSACTIONS filtration and ion exchange columns. The enzyme, which elutes at 125 mM-NaC1 from DEAE-columns, needs the presence of calcium, and is optimally active in the neutral to basic pH range. In addition, this enzyme turned out to be heat labile and, surprisingly, tolerated detergent (cholate and Triton). A molecular mass of PLA,-M within the range 14 000-18 000 Da was indicated, as described for most of the PLA,s purified to date. PLA, was also partially purified from the placental 100000 g supernatant (S100 cytosol). This was achieved by subjecting the cytosol to sequential ion exchange chromatography steps. At least three distinguishable cytosolic PLA, activities were obtained. One resembled PLA,-M in all the properties mentioned and it is this enzyme which we named PLA,-S. Other parameters, especially heat lability and detergent tolerance, distinguished PLA,-M and PLA,-S from pancreatic PLA, and, therefore, we assigned these placental enzymes to the non-pancreatic type phospholipases A, (group I1 PLA,s). During the course of PLA, purification we found potent PLA, inhibitory activity attached to placental membranes. Together with PLA,-M a large portion of this activity could be released by EGTA-extraction. When we next incubated the extracted membranes with liposomes we found the remaining membrane-bound PLA, activity enhanced compared to membranes before extraction. This and other findings let us conclude that only following the removal of the inhibitors can liposome phospholipid be attacked by membrane-residing PLA,. We also provided evidence that it is the inhibitory activity which sequestrates liposomes and leaves PLA, unemployed [6] . In the meantime, we have separated this activity and identified six fractions with proteins which were immunologically characterized as eight different lipocortins [7] .
Local and circulating levels of PLA, are elevated during infections, inflammatory diseases and tissue injury and it is thought that it is this extracellular PLA, which contributes to cellular tissue damage 181. In this communication we asked whether PLA, from three different sources has the potency to attack intact cells and release arachidonic acid. Moreover, we looked at whether lipocortins exogenously added to cells would possibly affect PLA, action. Cells of the tumour cell line JEG-3 were metabolically labelled with [ 1-14C]-arachidonic acid ( A A ) for 24 h. After this time we found that the radioactivity incorporated predominantly into the phospholipids, with phosphatidylcholine as the major species. When we tried PLA,-S, pancreatic PLA, and bee venom PLA, as possible stimulators of A A release we found that these enzymes increased A A release only marginally over the background (Fig. 1) . Next we used melittin in our cell system as it is known to act synergistically with the bee venom PLA, 191. Indeed, this also turned out to be the case in our cell system. However, neither the placental nor the pancreatic PLA, were affected. In this context, it should be pointed out that we have often found commercially available melittin preparations contaminated by PLA, which we had to destroy first by heat inactivation. Further, it needs to be said that our efforts to inhibit melittin-stimulated PLA, by lipocortins in the cell culture system have failed. In trying to stimulate A A release by effectors other than PLA, we have found a significant release induced by the calcium ionophore A23 187. Surprisingly, this release could be inhibited by lipocortin addition (Fig. 1 ) .
In summary, both local and systemic inflammatory processes have been associated with high levels of extracellular PLA, activity [8] . However, our data do not appear to substantiate such a concept, at least as far as porcine pancreatic, placental non-pancreatic type PLA, and choriocarcinoma cells are concerned. Although these enzymes do not seem to be suited for extracellular action, PLA, of lysosoma1 origin cannot be excluded as a membrane injuring enzyme. On the other hand, pancreatic and non-pancreatic type enzymes may need a melittin-type cofactor for activity [lo] . Most interestingly, however, is that lipocortins do not withhold melittin-dependent bee venom PLA, from attacking cells. In contrast, A A release induced by calcium ionophore can be suppressed if lipocortins were allowed to act before ionophore administration. Whether this is of any physiological relevance remains to be elucidated. The most simple explanation would, however, be that lipocortins bind ionophore and thus prevent it from reaching the cell membrane.
